What this is
- How it works
- How it works isn't classified yet
- Tested for
- Peanut Allergies
- Main trialPhase 1
- “The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or two doses of MY006 or a placebo, administered by subcutaneous injection. The safety of MY006, including the number of adverse events, injection-site reactions, and immunogenicity, in these participants will be reviewed by an independent Safety Monitoring Committee and, if the safety is judged…”In the company’s words, NCT07287033 on ClinicalTrials.gov
Other drugs for Peanut Allergies
- Viaskin PeanutDBV Technologies · Phase 3
- RemibrutinibNovartis · Phase 3
- UKK-0018Ukko Inc · Phase 1/2
- RPT904RAPT Therapeutics, Inc., a member of the GSK plc group of companies · Phase 2
- ENP-501N-Fold, LLC · Phase 1/2
- LP-003Longbio Pharma · Phase 2
Coming up1
- Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Apr 2027 | Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026